Terms: = Brain cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Treatment
913 results:
1. Trastuzumab deruxtecan versus trastuzumab emtansine in her2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.
Hurvitz SA; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Egorov A; Liu Y; Cathcart J; Bako E; Tecson K; Verma S; Cortés J
ESMO Open; 2024 May; 9(5):102924. PubMed ID: 38796287
[TBL] [Abstract] [Full Text] [Related]
2. MR-based radiomics predictive modelling of EGFR mutation and her2 overexpression in metastatic brain adenocarcinoma: a two-centre study.
Li Y; Jin Y; Wang Y; Liu W; Jia W; Wang J
Cancer Imaging; 2024 May; 24(1):65. PubMed ID: 38773634
[TBL] [Abstract] [Full Text] [Related]
3. Trastuzumab deruxtecan in previously treated her2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
Petit T; Hajjaji N; Antoine EC; Benderra MA; Gozy M; Foa C; Mouysset JL; Grenier J; Mousseau M; Mailliez A; Saghatchian M; Lachaier E; Desmoulins I; Hennequin A; Maes P; Loirat D; Ricci F; Diéras V; Berton D; Tiong FL; Teixeira L; Dohollou N; Lévy C; Bachelot T; Pierga JY
Cancer Med; 2024 May; 13(9):e7168. PubMed ID: 38733172
[TBL] [Abstract] [Full Text] [Related]
4. cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to her2-targeting therapies.
Goyette MA; Stevens LE; DePinho CR; Seehawer M; Nishida J; Li Z; Wilde CM; Li R; Qiu X; Pyke AL; Zhao S; Lim K; Tender GS; Northey JJ; Riley NM; Long HW; Bertozzi CR; Weaver VM; Polyak K
Proc Natl Acad Sci U S A; 2024 May; 121(20):e2322688121. PubMed ID: 38709925
[TBL] [Abstract] [Full Text] [Related]
5. Tucatinib Combination treatment After Trastuzumab-Deruxtecan in Patients With erbb2-Positive Metastatic Breast cancer.
Frenel JS; Zeghondy J; Guérin-Charbonnel C; Mailliez A; Volant E; Poumeaud F; Patsouris A; Arnedos M; Bailleux C; Cabal J; Galland L; de Nonneville A; Guiu S; Dalenc F; Pistilli B; Bachelot T; Pierga JY; Le Du F; Bocquet F; Larrouquere L; Loirat D
JAMA Netw Open; 2024 Apr; 7(4):e244435. PubMed ID: 38568692
[TBL] [Abstract] [Full Text] [Related]
6. Prediction of cognitive decline in older breast cancer survivors: the Thinking and Living with cancer study.
McDeed AP; Van Dyk K; Zhou X; Zhai W; Ahles TA; Bethea TN; Carroll JE; Cohen HJ; Nakamura ZM; Rentscher KE; Saykin AJ; Small BJ; Root JC; Jim H; Patel SK; Mcdonald BC; Mandelblatt JS; Ahn J
JNCI Cancer Spectr; 2024 Feb; 8(2):. PubMed ID: 38556480
[TBL] [Abstract] [Full Text] [Related]
7. Factors associated with overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review.
Wallace G; Kundalia R; Vallebuona E; Cao B; Kim Y; Forsyth P; Soyano A; Smalley I; Pina Y
Breast Cancer Res; 2024 Mar; 26(1):55. PubMed ID: 38553702
[TBL] [Abstract] [Full Text] [Related]
8. Human Epidermal Growth Factor Receptor 2-Low Breast cancer brain Metastases: An Opportunity for Targeted Systemic Therapies in a High-Need Patient Population.
Chehade R; Nofech-Mozes S; Plotkin A; Fan KY; Das S; Sahgal A; Moravan V; Jerzak KJ
JCO Precis Oncol; 2024 Mar; 8():e2300487. PubMed ID: 38547418
[TBL] [Abstract] [Full Text] [Related]
9. Palbociclib in Older Patients with Advanced/Metastatic Breast cancer: A Systematic Review.
Brain E; Chen C; Simon S; Pasupuleti V; Pfitzer KV; Gelmon KA
Target Oncol; 2024 May; 19(3):303-320. PubMed ID: 38546943
[TBL] [Abstract] [Full Text] [Related]
10. Intracranial Efficacy of Pyrotinib and Capecitabine Combination Therapy in her2-Positive Breast cancer with brain Metastases.
Wang C; Xiang J; Zhang Q; Li J; Liu Y; Liu J
Drug Des Devel Ther; 2024; 18():909-917. PubMed ID: 38545432
[TBL] [Abstract] [Full Text] [Related]
11. Protecting the brain: Novel Strategies for Preventing Breast cancer brain Metastases through Selective Estrogen Receptor β Agonists and In Vitro Blood-brain Barrier Models.
Kirchner J; Völker E; Shityakov S; Saji S; Förster CY
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542355
[TBL] [Abstract] [Full Text] [Related]
12. Survival Analysis of Male Patients with brain Metastases at Initial Breast cancer Diagnosis over the Last Decade.
Avila J; Leone J; Vallejo CT; Leone JP
Med Sci (Basel); 2024 Mar; 12(1):. PubMed ID: 38535156
[TBL] [Abstract] [Full Text] [Related]
13. Targeted dual degradation of her2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in her2-positive breast cancer models.
Yang L; Bhattacharya A; Peterson D; Li Y; Liu X; Marangoni E; Robila V; Zhang Y
Drug Resist Updat; 2024 May; 74():101078. PubMed ID: 38503142
[TBL] [Abstract] [Full Text] [Related]
14. Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management.
Strickland MR; Lander EM; Gibson MK; Ilson DH; Ajani JA; Klempner SJ
J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38503041
[TBL] [Abstract] [Full Text] [Related]
15. DEGRO guideline for personalized radiotherapy of brain metastases and leptomeningeal carcinomatosis in patients with breast cancer.
Borm KJ; Behzadi ST; Hörner-Rieber J; Krug D; Baumann R; Corradini S; Duma MN; Dunst J; Fastner G; Feyer P; Fietkau R; Haase W; Harms W; Hehr T; Matuschek C; Piroth MD; Schmeel LC; Souchon R; Strnad V; Budach W; Combs SE;
Strahlenther Onkol; 2024 Apr; 200(4):259-275. PubMed ID: 38488902
[TBL] [Abstract] [Full Text] [Related]
16. Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population.
Lu Q; Wang N; Jiang K; Zhou H; Zhang P; Zhang J; Wang S; Sun P; Xu F
ESMO Open; 2024 Mar; 9(3):102389. PubMed ID: 38460250
[TBL] [Abstract] [Full Text] [Related]
17. Detection of her2 expression using
Zhao L; Xing Y; Liu C; Ma S; Huang W; Cheng Z; Zhao J
Breast Cancer Res; 2024 Mar; 26(1):40. PubMed ID: 38459598
[TBL] [Abstract] [Full Text] [Related]
18. Survival analysis of patients with brain metastases at initial breast cancer diagnosis over the last decade.
Avila J; Leone J; Vallejo CT; Lin NU; Leone JP
Breast Cancer Res Treat; 2024 Jun; 205(3):579-587. PubMed ID: 38453783
[TBL] [Abstract] [Full Text] [Related]
19. Impact of the Breast cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study.
Sanft TB; Wong J; O'Neal B; Siuliukina N; Jankowitz RC; Pegram MD; Fox JR; Zhang Y; Treuner K; O'Shaughnessy JA
J Natl Compr Canc Netw; 2024 Mar; 22(2):99-107. PubMed ID: 38437792
[TBL] [Abstract] [Full Text] [Related]
20. Synchronous double primary small cell lung cancer and invasive ductal breast carcinoma: a case report.
Gan J; Liu M; Liu F; Wen J; Fu W; Jia J
BMC Pulm Med; 2024 Feb; 24(1):93. PubMed ID: 38388422
[TBL] [Abstract] [Full Text] [Related]
[Next]